MicroRNAs (miRNAs) are short, non-coding RNA molecules that fine tune posttranscriptional protein expression. Aging is accompanied by progressive declines in muscle mass and strength, and in bone mineral density (BMD). Although miRNAs in pathology have been extensively studied, the role of circulating miRNAs (c-miRNAs) in osteoporosis and sarcopenia has to date not been well understood. The purpose of this study was to examine the difference in bone and muscle specific c-miRNAs in postmenopausal women based on their bone and muscle status, and to determine the associations between these specific c-miRNAs and muscle and bone variables. Seventy-five postmenopausal women aged 60 to 85 years old participated in this study. Body composition and BMD, functional performance tests (grip strength, gait speed, and countermovement jumps) were assessed. Levels of c-miRNAs (miR-1-3p, -21-5p, -23a-3p, -24-3p, -100-5p, -125b-5p, -133a-3p, -206) and bone turnover markers were analyzed. Statistically, there were no significant differences in specific c-miRNAs based on sarcopenia and osteoporosis status. However, fold changes of miR-21-5p (FC = 2.59) and -23a-3p (FC = 2.09) indicated upregulation and miR-125b-5p (FC = 0.46) indicated downregulation in the osteoporotic group compared to the non-osteoporotic group. The relative expression level of miR-125b-5p was significantly positively correlated with age (p < 0.05). The relative expression level of miR-21-5p was significantly negatively correlated with trochanter BMC (p < 0.05). Furthermore, the relative expression level of miR-23a-3p was significantly positively correlated with TRAP5b levels (p < 0.05). Although no statistical differences were found in target c-miRNAs based on muscle and bone status, our results indicate that there are biological differential expressions in some c-miRNAs between osteoporotic and non-osteoporotic individuals. Other circulating miRNAs need to be studied in the future.
Keywords: MicroRNA; Osteoporosis; Postmenopausal women; Sarcopenia.
Published by Elsevier Inc.